Immutrin, a biotech company developing antibody therapy for amyloidosis, has appointed Dr. Robert Blaustein as Chief Medical Officer. Blaustein brings over 15 years of cardiovascular drug development experience from Edgewise and Merck. He will lead clinical and regulatory strategies as Immutrin prepares for first-in-human studies of its lead therapy targeting ATTR cardiomyopathy. The company also established a US subsidiary to support clinical activities in North America, marking a key step toward becoming a clinical-stage organization.
US stock futures gained following a mixed market close and President Trump's approval of Nvidia's H200 AI chip sales to Chinese firms, although China has halted deliveries. Economic data showed a 0.5% rise in April retail sales and a slight increase ...
Sumitomo Forestry has finalized its acquisition of Tri Pointe Homes for $47 per share, making Tri Pointe a wholly owned subsidiary and delisting it from the NYSE. This deal expands Sumitomo Forestry's U.S. homebuilding presence to 18 states, deliveri...
Verde Resources Inc. announced its invitation to the GenZero Climate Summit 2026 in Singapore, a key event focused on advancing net zero solutions. The company aims to expand its presence in Singapore and Southeast Asia, leveraging its newly establis...
Boeing shares rose following Treasury Secretary Scott Bessent's indication of significant aircraft orders from China during President Trump's meeting with Chinese President Xi Jinping. The U.S.-China tariff dispute had previously halted Boeing delive...
INmune Bio announced that the FDA granted Fast Track designation to its drug XPro1595 for treating early Alzheimer's disease, including mild cognitive impairment and mild dementia stages. This designation aims to speed up the development and review p...
